OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013...
Expanding OGX-427 Clinical Development Program Demonstrates the Company's Commitment to Addressing the Challenge of Cancer Treatment Resistance "Trials in Progress" Posters will be Presented for...
View ArticleGene mutation gives boost to brain cancer cells (University of California)
(Source: University of California) An international team of researchers - led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the...
View ArticleAnalyses of MPACT Trial Evaluating ABRAXANE® Combination Therapy for the...
Data Suggest Treatment with ABRAXANE plus Gemcitabine Reduces Levels of CA19-9 and Increases the Frequency of PET Responses; Both Tools Found to be Potential Prognostic Factors of Overall Survival 2013...
View ArticleProtein linked with tumor growth could be potential target for...
(Source: University of Colorado System) A team of researchers led by the University of Colorado Boulder has discovered a protein complex that could be targeted with drugs to stunt tumor growth. As...
View ArticleSynta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3...
(Source: Synta Pharmaceuticals Corporation) Synta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer - Data presented at...
View ArticleGenentech Announces Final Phase III Study Results of Avastin Plus...
Tweet Send to a Friend CHICAGO--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced final results from the Phase III AVAglio study in people with...
View ArticleTrametinib, the first MEK inhibitor, received U.S. regulatory approval, JT's...
(Source: Japan Tobacco Inc) FOR IMMEDIATE RELEASE Tokyo, May 30, 2013 Trametinib, the first MEK inhibitor, received U.S. regulatory approval, JT's licence partner GlaxoSmithKline announced A New Drug...
View ArticleGenentech Announces Final Phase III Study Results of Avastin Plus...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced final results from the Phase III AVAglio study in people with newly diagnosed glioblastoma, the most common and...
View ArticlePotential new way to suppress tumor growth discovered (University of California)
(Source: University of California) Researchers at the University of California, San Diego School of Medicine, with colleagues at the University of Rochester Medical Center, have identified a new...
View ArticlebioMérieux Receives FDA Approval for THxIDTM-BRAF Companion Diagnostic Test...
(Source: BioMérieux SA) Marcy l'Etoile, France - May 30th, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its novel molecular test THxIDTM-BRAF received...
View ArticleSynta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3...
Tweet Send to a Friend Get Alerts SNTA Hot Sheet Price: $7.38 --0% Overall Analyst Rating: BUY ( Down) Revenue Growth %: -100.0% Trade SNTA Now! – Data presented at ASCO 2013 – – Median overall...
View ArticlePotential new way to suppress tumor growth discovered
Writing in this week's online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), Willis X. Li, PhD, a professor in the Department of Medicine at UC San Diego, reports that a...
View ArticleDrug is a first to help patients with melanoma of the eye
CHICAGO (Reuters) - In his first few weeks as head of the melanoma group at Memorial Sloan-Kettering Cancer Center seven years ago, a young man walked into Dr. Gary Schwartz's office with a rare form...
View ArticleIsis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients...
(Source: Isis Pharmaceuticals Inc) CARLSBAD, Calif., June 3, 2013/PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with...
View ArticleHow brain cancer cells survive and drive tumor growth
Washington, June 01: An international team of researchers has found that a singular gene mutation helps brain cancer cells to not just survive, but grow tumors rapidly by altering the splicing of genes...
View ArticlePromising drug prevents cancer cells from shutting down immune system (Yale...
(Source: Yale University) May 31, 2013 An investigational drug that targets the immune system's ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients with a variety...
View ArticleResearchers Identify Genetic Signature of Deadly Brain Cancer (University of...
(Source: University of Rochester) A multi-institutional team of researchers have pinpointed the genetic traits of the cells that give rise to gliomas - the most common form of malignant brain cancer....
View ArticleIsis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients...
CARLSBAD, Calif., June 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the...
View ArticleMetastatic breast cancer study shows success in finding new treatment
The Side-Out Foundation's pilot study is part of cutting-edge approach to personalized medicine that looks beyond genomic analysis alone to combine it with what some say is the next frontier in...
View ArticleNewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy...
(Source: NewLink Genetics Corporation) AMES, Iowa, June 3, 2013/PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy,...
View Article
